This article is more than 5 years old. Information may no longer be current.

Oxigene reports positive preliminary results for myopic macular degeneration drug

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

WALTHAM, Mass. — A combretastatin A4 phosphate drug for myopic macular degeneration prevented vision loss without serious adverse events in a phase 2 trial, according to a press release from Oxigene, the drug's manufacturer.

In the double-masked, dose-ranging, multicenter study, 23 subjects received the drug intravenously at doses of 27, 36 or 45 mg/m². All patients received two doses 1 week apart with up to three additional doses. At 3 months' follow-up, 100% of patients met the study's primary efficacy endpoint of less than a three-line loss in visual acuity, according to the release.

Full results from the trial will be presented at the annual meeting of the Association for Research in Vision and Ophthalmology in Fort Lauderdale, Fla., in May, according to the release.

Oxigene officials also announced their intention to further develop eye drop and ocular mini-tab formulations of the drug after meeting with the U.S. Food and Drug Administration, according to the release.